Abstract: Runner assembly 10 for carrying a receptacle 12 towards and away from a structure 14. The runner assembly 10 includes: at least one pair of first bearings 16, each first bearing 16 being mountable to the structure 14 so that the first bearings 16 of the, or each, pair are spaced apart; an elongate runner 18 defining a longitudinal length and having an opposed pair of first tracks 22 spaced from each other, each first track 22 configured to cooperate with the first bearings 16 to allow the runner 18 to be carried by the first bearings 16; at least one second bearing 24 mounted to the runner 18; and an elongate track member 26 mountable to the receptacle 12, the track member 26 having a second track 28 defining at least one pair of opposed bearing surfaces 30, 31 spaced from each other and configured to cooperate with the at least one second bearing 24 to allow the track member 26 to be carried by the at least one second bearing 24.

Abstract: A sequence of polymer units in a polymer (3), eg. DNA, is estimated from at least one series of measurements related to the polymer, eg. ion current as a function of translocation through a nanopore (1), wherein the value of each measurement is dependent on a k-mer being a group of k polymer units (4). A probabilistic model, especially a hidden Markov model (HMM), is provided, comprising, for a set of possible k-mers: transition weightings representing the chances of transitions from origin k-mers to destination k-mers; and emission weightings in respect of each k-mer that represent the chances of observing given values of measurements for that k-mer. The series of measurements is analysed using an analytical technique, eg. Viterbi decoding, that refers to the model and estimates at least one estimated sequence of polymer units in the polymer based on the likelihood predicted by the model of the series of measurements being produced by sequences of polymer units.

Abstract: A reagent composition for delivery nucleic acid therapeutics to cells is provided. The reagent includes ionizable lipid, structural lipid, and a stabilizing agent which improves the transfection efficiency of nucleic acids, and leaves transfected cells viable. The 5 transfection reagent is effective in plasmid and mRNA delivery, and in neurons and progenitor-like cells. It may be used for ex vivo cell therapy.

Abstract: The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) where R1 features an amine group, particularly useful in the formulation of lipid particles including nucleic acid therapeutic agents, or proteins, or both, and for delivery of nucleic acid and protein therapeutics to cells in vivo or ex vivo, including anticancer and vaccine applications.

Abstract: The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) Wherein R1 includes an amino group. These compounds are particularly useful in the formulation and in vivo and ex vivo delivery of nucleic acid and protein therapeutics for preparing and implementing T cell transfection, gene editing, cancer therapies, cancer prophylactics, and in the preparation of vaccines.

Abstract: There is provided a lipid mix composition comprising ionizable lipid, a structural lipid such as DSPC, a sterol, and a surfactant such as polysorbate 80, polyoxyethylene (10) stearyl ether, polyoxyethylene (20) stearyl ether, or D-?-Tocopherol polyethylene glycol 1000 succinate. The lipid mix compositions find particular use in transfecting difficult to transfect cells and maintaining the viability of those cells. The lipid mix compositions are particularly well suited to T cell transfection ex vivo.

Abstract: A reagent composition for delivery nucleic acid therapeutics to cells is provided. The reagent includes ionizable lipid, structural lipid, and a stabilizing agent which improves the transfection efficiency of nucleic acids, and leaves transfected cells viable. The 5 transfection reagent is effective in plasmid and mRNA delivery, and in neurons and progenitor-like cells. It may be used for ex vivo cell therapy.